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Multiple myelomaAbstract Introduction: Multiple myeloma (MM) accounts for approximately 0.8% of all cancer
diagnoses and 0.9% of cancer deaths. Leptin receptors were expressed on CD34+ cells. Resistin
receptors were expressed on inﬂammatory cells and pro-inﬂammatory cytokines increase the expres-
sion of resistin on monocytes.
Aim of work: To assess the level of leptin and resistin in non-obese multiple myeloma patients and
to study their relation with Ig level and disease stage.
Subjects & methods: 32 subjects were included; 16 patients diagnosed with MM and 16 healthy
individuals served as control. All were subjected to history taking, clinical examination, routine lab-
oratory investigations and leptin & resistin blood level. Laboratory investigations were done for
diagnosis and staging for MM patients.
Results: Leptin was signiﬁcantly higher in MM patients compared with the control group, unlike
resistin which showed no signiﬁcant difference between the two groups. A signiﬁcant positive rela-
tion was found between IgG level & leptin. Similarly, a signiﬁcant difference in leptin level has been
observed between stage I & stage II (higher in II).
Conclusions: Leptin may play a role in the pathogenesis of MM and its level may be changed in
different stages.
ª 2014 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.D license.Introduction
Multiple myeloma (MM) is a common hematological malig-
nancy [1]. It accounts for approximately 0.8% of all cancer
diagnoses and 0.9% of cancer deaths [2]. MM affects mostly
older people with a median age of approximately 70 years.
Blacks are more likely to be affected than whites (2:1) and
MM is slightly more common in males than females [1].
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etiology of MM [3,4]. As adipose tissue expands in obesity,
the amount of anti-inﬂammatory adipokines, particularly
adiponectin, decreases and the amount of pro-inﬂammatory
adipokines with an oncogenic potential, such as leptin, resi-
stin, visfatin and chemerin, and cytokines such as tumor
necrosis factor-a (TNF-a), interleukin (IL)-1 and IL-6 in-
creases [5]. The evidence from studies showed that apart from
energy storing, adipose tissue also acts as an endocrine organ.
Preserving the balance between the levels of adipocytokines
secreted from adipose tissue is important [6]. Adipokines exert
signiﬁcant effects on metabolism and lipogenesis as well as in
regulation of human inﬂammatory responses [7]. These
adipocytokines especially leptin and resistin are widely
investigated [8].
Leptin increases the glucose uptake and glucose cycle in
cells independent of insulin. Recent studies indicated that lep-
tin is also associated with growth [9]. In vitro cancer studies
demonstrated that leptin has mitogenic effects and increases
migration and growth factors [10].
The ﬁndings that leptin expression can be induced rapidly
by inﬂammatory stimuli such as IL-1 and TNF-a during the
acute phase of immune response indicate a role for leptin act-
ing as a mediator in regulating stimulatory capacity on T cells
[11]. In monocytes and macrophages, leptin has been shown
to stimulate proliferation and phagocytosis, together with
production of pro-inﬂammatory cytokines [12]. Furthermore,
leptin has been shown to promote the survival of both T and
B lymphocytes by suppressing apoptosis [11,13]. Leptin also
increases the production of a variety of proinﬂammatory
cytokines such as IFN-c and IL-2 in T lymphocytes [14].
Functional leptin receptors are found to be expressed on
diverse cancer cells derived from different tissues such as
breast, colon or prostate [15–17]. The best evidence that leptin
can indeed be involved in neoplastic processes has been pro-
vided by studies on breast and colorectal cancer models, while
the results for other cancer types are very limited and often
inconsistent or inconclusive [18]. Receptors for leptin have
been identiﬁed in several myeloid and lymphoid leukemic cell
lines [19,20].
Resistin is one of white adipose tissue adipocytokines [21].
Plasma resistin levels were reported to be associated with
many inﬂammatory markers [22]. Resistin shares several fea-
tures with proinﬂammatory cytokines and can play a role in
the regulation of inﬂammation and immunity [23]. The
majority of epidemiologic studies had indicated that in vivo
hyper-resistinemia is associated with some obesity-related
malignancies such as colon cancer and prostate cancer [24].
Elevated levels of plasma resistin have been found in females
with breast cancer, and higher levels appear related to the
highest histological grade [25]. Furthermore, resistin levels
are signiﬁcantly higher in lymphoma patients than in patients
with other hematological malignancies [26]. Although only a
few studies have analyzed resistin in patients with malignan-
cies, the general properties of resistin could contribute to
tumorigenesis [27]. Thus, the distinct possibility exists that
obesity may be linked to MM through altered secretion of
one of these adipokines [26,28].So, the aim of this current study was to assess leptin and
resistin levels in non-obese multiple myeloma patients and
study their relation with Ig level and disease stage.
Subjects and methods
The present study was carried out on 32 subjects selected
from out-patient’s clinic & in-patient’s wards of the Internal
Medicine Department (Hematology unit), Tanta University
Hospital, from 10/2011 until 10/2013.
All patients were initially diagnosed before taking treat-
ment. All participants provided written informed consent.
The subjects of this study were classiﬁed into two groups.
Group 1
It included 16 patients with histopathologically conﬁrmed
multiple myeloma according to World Health Organization
(WHO) diagnostic criteria for symptomatic multiple myeloma
[29], 6 males & 10 females, their ages ranged from 51 to
61.5 years (55.7 ± 3.47). Eight patients were in stage I and
8 patients were in stage II, according to the Durie–Salmon
staging [30]. None of the patients were in stage III. All
patients were MM IgG.
Group 2
It included 16 healthy subjects as a control group of matching
age and sex, 6 males & 10 females; their ages ranged from 50 to
61 years (55.46 ± 3.98).
Inclusion criteria
Newly diagnosed patients histopathologically conﬁrmed mul-
tiple myeloma according to WHO diagnostic criteria for
symptomatic multiple myeloma.
Exclusion criteria
Patients or controls with: documented infection within the
last 2 weeks, hypertension, diabetes, hyperlipidemia, obesity
(body mass index [BMI] > 24.9), or insulin resistance state
(using homeostatic model assessment of insulin resistance
[HOMA-IR] formula) (to eliminate the effect of those factors
on leptin and resistin levels). Patients with febrile neutropenia,
sepsis, any organ failure (kidney, liver, lung, heart) were
excluded.Methods
All patients and controls were subjected to the following: Full
history taking, complete clinical examination, routine labora-
tory investigations including: complete blood count (CBC),
serum total cholesterol, HDL, LDL & triglycerides, Erythro-
cyte sedimentation rate (ESR), C-reactive protein (CRP),
LDH, liver and kidney function tests and serum leptin and
resistin using enzyme-linked immunosorbent assay (ELI-
SA)[31,32]. MM patients were diagnosed according to
Table 2 Relation between leptin and resistin with both IgG
level & Plasma cell% in MM patients.
Leptin Resistin
Spearman r P value Spearman r P value
IgG 0.585 0.017 0.102 0.79
Plasma cells 0.092 0.81 0.406 0.323
correlation between Leptin and IgG
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Figure 1 Correlation between leptin level and IgG level in MM
patients.
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to the Durie–Salmon staging system [30]. All blood specimens
were collected prior to the initiation of chemotherapy or
blood transfusions for the patient’s group.
Leptin by ELISA method [31]
Serum leptin level was measured using the enzyme-linked
immunosorbent assay method ELISA (R&D system Poston
Biochem, 840 Memorial Dravee, Cambridge). The sensitivity
of the assay was 7.8 pg/ml. The intra-assay coefﬁcient of vari-
ation was 3.1%, while the inter-assay coefﬁcient of variation
was 4.3%.
Resistin by ELISA method [32]
Serum resistin level was measured using the enzyme-linked
immunosorbent assay method ELISA (R&D system Poston
Biochem, 840 Memorial Dravee, Cambridge). The sensitivity
of the assay was 0.055 ng/ml. The intra-assay coefﬁcient of
variation was 4.7%, while the inter-assay coefﬁcient of varia-
tion was 8.4%.
Statistical analysis
Comparisons between cases and controls were conducted by
using chi-square test for categorical variables and Mann Whit-
ney test for comparing means. Spearman correlation test was
used to examine the relations of both leptin and resistin, and
metabolic characteristics.
P value less than 0.05 was considered statistically signiﬁ-
cant. All analyses were performed using SPSS statistical soft-
ware (SPSS V.16, Inc., Chicago, IL).
Results
The current work included 16 patients diagnosed with MM; 6
males (37.5%) & 10 females (62.5%); their ages ranged from
51 to 61.5 years (55.7 ± 3.47). According to the Durie–Salmon
staging, 8 patients were in stage I & 8 patients were in stage II.
None of the patients were in stage III. All patients were MM
IgG.
The control group included 16 healthy subjects, 6 males
(37.5%) & 10 females (62.5%), their ages ranged from 50 to
61 years (55.4 ± 3.98). MM cases and controls were matched
by gender and age.
MM cases had signiﬁcantly higher levels of ESR 1st hour
(P< 0.0001) and LDH (P< 0.0001) in comparison to controlTable 1 Descriptive characteristics of patients with multiple myelo
Character MM patients
n= 16
Sex M/F 6/10
Age in years mean ± SD 55.7 ± 3.47
ESR 1st hour mm mean ± SD 81.5 ± 13.64
LDH (U/L) mean ± SD 395 ± 67.63
Leptin ng/ml mean ± SD 5.82 ± 1.43
Resistin ng/ml mean ± SD 1.56 ± 0.74subjects. Leptin levels of controls were signiﬁcantly lower than
that of MM cases (P< 0.0001), on other hand, no signiﬁcant
difference was found in resistin level between MM cases and
control (P= 0.438), (Table 1).
In MM patients, we found a signiﬁcant positive correlation
between leptin level and IgG level (P= 0.017). However, no
relation had been detected between leptin level & Plasma cell%
(P= 0.81). Regarding resistin, we could not ﬁnd any relation
between its level and IgG level or plasma cell% in MM
(P= 0.79 and 0.323), respectively (Table 2 and Fig. 1).
We also found a signiﬁcant difference in leptin level in dif-
ferent grades of MM, as leptin was signiﬁcantly higher in grade
II (P= 0.032) in comparison to grade I (Table 3). On the con-
trary, resistin showed no signiﬁcant difference in its level in
grades I and II (P= 0.937) (Table 3).
Regarding ESR 1st hour and LDH levels in MM, both
demonstrated a signiﬁcant positive correlation with leptin level
(P= 0.029 and 0.002, respectively) (Table 4 and Figs. 2 and
3).
On the other hand, LDH had a signiﬁcant negative
correlation with resistin level (P= 0.047), while ESR showed
no signiﬁcant correlation with resistin level (P= 0.534)
(Table 4 and Fig. 4).ma (n= 16) and controls (n= 16).
Control P value
n= 16
6/10 P= 1
55.46 ± 3.98 P= 0.609
8.75 ± 1.65 P< 0.0001
273.13 ± 69.45 P< 0.0001
2.16 ± 0.72 P< 0.0001
1.6 ± 0.68 P= 0.438
Table 4 Correlation of leptin and resistin levels with both
ESR and LDH in MM patients.
Leptin Resistin
Spearman r P value Spearman r P value
ESR 1st hour 0.544 0.029 0.148 0.534
LDH 0.705 0.002 0.501 0.047
correlation between Leptin and ESR
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Figure 2 Correlation between leptin and ESR in MM patients.
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Figure 3 Correlation between leptin and LDH in MM patients.
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Figure 4 Correlation between resistin and LDH in MM patients.
Table 3 Comparison between LEPTIN and resistin levels in
stages I and II in MM patients.
MM stage Mean SD P value
Leptin Stage I 4.62 1.1 0.032
Stage II 6.74 0.81
Resistin Stage I 1.53 0.85 0.937
Stage II 1.47 0.62
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Leptin is an important regulator of caloric intake and energy
expenditure, and recent studies have linked obesity to a dysreg-
ulated leptin metabolism [33]. Modulating adipokines could be
particularly an attractive goal for cancer prevention. Regular
moderate exercise, adoption of a balanced diet, weight reduc-
tion and bariatric surgery for morbidly obese persons mayincrease plasma adiponectin [34], and decrease plasma leptin,
resistin, reducing thus the risk of developing cancer. Very re-
cently, L-4F, an apolipoprotein peptide mimetic used for the
pharmacologic upregulation of adiponectin, decreased multi-
ple myeloma (MM) tumor burden through induction of apop-
tosis, increased survival of myeloma-bearing mice and
provided protection against myeloma destructive osteolytic
bone disease, an important clinical feature of MM [35].
In the present study, we investigated the following: the level
of leptin & resistin in non obese patients with MM; the relation
of leptin & resistin with other parameters in MM such as ESR
and LDH, and the relation between leptin & resistin levels with
the staging of MM and IgG level.
As regards leptin & multiple myeloma (MM), we found
that the level of the leptin was signiﬁcantly higher in the
MM patients when compared with the control group
(P< 0.0001).We also found a positive signiﬁcant correlation
between IgG level & leptin in MM patients (P= 0.017), on
other hand, there was no signiﬁcant relation between bone
marrow plasma cells % & leptin (P= 0.81). Moreover, we
found a signiﬁcant difference in leptin level between stage I
& stage II in MM patients (the level was higher in stage II)
(P= 0.032). Regarding ESR 1st hour and LDH levels in
MM, both had a signiﬁcant positive correlation with leptin le-
vel (P= 0.029 and 0.002, respectively).
The results in this work were partially in accordance with
those of Alexandrakis et al. [28] who found that leptin was sig-
niﬁcantly higher in the newly diagnosed MM patients than in
controls. However, the authors disagreed with us when they
added that; leptin did not increase with advancement of the
disease stage, and concluded that, Leptin serum levels do not
reﬂect disease severity in MM.
Our results were also in agreement with those of Pamuk
et al. [26] who found that mean leptin levels in MM patients
were signiﬁcantly higher than in the control group. Reseland
et al. [36] similarly found that Plasma leptin concentrations
were signiﬁcantly higher in the newly diagnosed patients com-
pared with the healthy control group.
Although Dalamaga et al. [37] found that MM patients
tend to have higher mean leptin levels than controls by univar-
iate analysis, which may reﬂect their higher degree of obesity.
Then they reported that after adjusting for age, gender, and
BMI, as well as for multiple comparisons performed, serum
leptin levels were not signiﬁcantly different between MM pa-
tients and controls. The rest of their results were in accordance
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with LDH. Leptin levels were also signiﬁcantly different
among multiple myeloma stages. Higher stages tend to present
higher levels of leptin .The differences in mean leptin levels by
stage were not small.
Similarly, in a recent study carried out by Hofmann et al.
[38], the authors found that patients with MM had higher level
of leptin (10.01 ± 2.64) in comparison to control (9.6 ± 2.71)
but not reaching a statistically signiﬁcant level. And they
added that, Leptin levels were not associated with MM risk.
Resistin was originally discovered as a molecule that in-
duced insulin resistance and caused hyperglycemia without
affecting peripheral insulin sensitivity [13]. However, data in
humans are controversial. In contrast to mice, resistin in hu-
mans is expressed in lower levels in adipocytes but at relatively
higher levels in circulating blood monocytes [39]. Moreover,
studies in humans have failed to detect higher serum resistin
levels in obese or insulin resistant subjects [40]. It is not known
if resistin can inﬂuence bone marrow hematopoietic activity or
immune responses, but the resistin gene is highly expressed in
bone marrow and leucocytes, indicating a probable regulatory
role in hematopoiesis [41].
As regards resistin & MM, we found that the level of the
resistin was lower in the MM patients when compared with
the control group but not reaching a signiﬁcant level
(P= 0.438). Also, we found insigniﬁcant correlation between
IgG levels & resistin in MM patients (P= 0.79). The same
was found in the relation between bone marrow plasma cells
% & resistin in MM patients which was insigniﬁcant
(P= 0.323). As regards staging in MM patients, we found
insigniﬁcant difference in resistin level between stage I & stage
II, (P= 0.937). Only LDH had a signiﬁcant negative correla-
tion with resistin level (P= 0.047).
The above mentioned results were in keeping with those of
Reseland et al. [36] who could not detect any signiﬁcant differ-
ences in the plasma concentrations of resistin between MM pa-
tients and controls.
Similar results were obtained by Pamuk et al. [26] who also
reported that the mean resistin levels in MM patients were
insigniﬁcantly higher than the control group.
In contrast, the above-mentioned data contradicted with
those of Dalamaga et al. [37] who found that the resistin levels
of control subjects were signiﬁcantly higher than levels of case
subjects (P< 0.0001). The authors also recorded that insignif-
icantly different resistin levels were found among different
prognostic stages and paraprotein classes.
The difference between our results & the others could be
attributed to the difference in the number of the patients;
moreover some authors did not consider selecting their pa-
tients based on the exclusion of the causes that could make a
difference in the leptin & resistin level such as obesity and
hyperlipdemia.
In summary, the results of our study suggest that leptin and
not resistin may play a role in the pathogenesis of MM
through its possible systemic effect, microenvironment, recep-
tor & gene expression, immunological changes & angiogenesis.
Also Leptin blood levels may be changed in MM patients with
different stages.
Agents that reduce cancer cell proliferation in conjunction
with high circulating levels of leptin should be evaluated for
use in the prevention and treatment of cancer [42].Yet, several enigmatic issues involving resistin receptor and
signaling pathways remain to be clariﬁed in order to unmask
its ontological role in cancer pathophysiology [43].
However the limitations of this study include: small sample
size, lack of multivariate regression models adjusting for sev-
eral variables, determinations of IL-6, and determination of
adiponectin.
Conclusion
Further studies are needed to investigate the possible prognos-
tic and therapeutic value of leptin and resistin in clinical prac-
tice of patients with MM.
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